Nevertheless, TNKSi predominantly leads to cell type-dependent and primary inhibition of the WNT/β-catenin, YAP, and PI3K/AKT signaling pathways and, subsequently, counteraction of MYC-driven cell cycle progression and tumor cell growth (Figure 2E). Here, AKT1 is linked to neoplasm.